Analysts' Top 5 Price Targets of June 11, 2025
Reading Time: 3 minutes
Avidity Biosciences [US05370A1088]: Citigroup reaffirms Buy rating and raises the price target from $70 to $75 (123% upside potential) The buy recommendation is based on a series of positive developments surrounding the company's leading drug, Del-Brax, which is being developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Avidity recently released promising topline data from the Phase 1/2 study "FORTITUDE." These positive results led the U.S. FDA to grant the drug an accelerated approval pathway. Avidity plans to submit...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
